There exists an unmet clinical need and widespread research interest to better understand the dose- concentration-response and adverse events relationships of immunosuppressive medications in transplant patients. The pediatric transplant community is missing a significant opportunity to optimize outcomes by focusing predominantly on trough concentrations and the area under the curve (AUC) of the blood concentrations as the most important parameters to correlate with empirical evidence of rejection. This application focuses on the development of mechanism based pharmacokinetic-pharmacodynamic (PK-PD) models that characterize the full concentration-effect relationship of immunosuppressive drugs on validated effect and clinical outcome measures. The structural PK-PD models will allow correlation of response and surrogate immunology biomarkers with computed concentrations at the target site. The proposed PPRU network study is designed to address the current information gap regarding age dependent disposition of mycophenolate mofetil (MMF, CellCept?) in pediatric renal transplant recipients and its potential impact on the exposure-response and toxicity relationships. In this application, research, advanced learning and mentoring agendas are formulated to describe the added value of the K24. The research agenda includes a population PK-PD study in pediatric kidney transplant patients. Particular attention is paid to the role of the K24 in facilitating secondary analyses particularly using biomarkers (Inosine Monophosphatase Dehydrogenase inhibition, CD25 expression and mitogenesis) for indirect response modeling. These models will serve to optimize therapy for each child. These analyses coupled with trial simulation can better predict research outcomes and rationalize trial design using biomarker and outcome data of the PK-PD study. The core PK-PD content illustrated by the MMF model has broad application in pediatric care and offers a paradigm to launch similar studies and mentoring opportunities across disciplines. The Pi's advanced learning agenda therefore is focused in mechanism based modeling and clinical trial simulation. The Pi's leadership in pediatric clinical pharmacology will serve the mentoring agenda and energize an accredited Clinical Pharmacology Program which the PI leads. Taken together, the research, advanced learning, and mentoring agendas synergize to promote practical and theoretical contributions to the optimization of drug studies for better treatment of MMF in pediatric transplant and pediatric care broadly.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
Pediatrics Subcommittee (CHHD)
Program Officer
Zajicek, Anne
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cincinnati Children's Hospital Medical Center
United States
Zip Code
Scott, Jeffrey R; Courter, Joshua D; Saldaña, Shannon N et al. (2016) Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum. Ther Drug Monit :
Emoto, Chie; Fukuda, Tsuyoshi; Mizuno, Tomoyuki et al. (2015) Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit 37:395-9
Chidambaran, Vidya; Venkatasubramanian, Raja; Sadhasivam, Senthilkumar et al. (2015) Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. Paediatr Anaesth 25:911-923
Sherwin, Catherine M T; Ngamprasertwong, Pornswan; Sadhasivam, Senthilkumar et al. (2014) Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study. Curr Clin Pharmacol 9:64-9
Dong, Min; Fukuda, Tsuyoshi; Cox, Shareen et al. (2014) Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol 78:1102-12
Smits, Thomas A; Cox, Shareen; Fukuda, Tsuyoshi et al. (2014) Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Ther Drug Monit 36:716-23
Fukuda, Tsuyoshi; Chidambaran, Vidya; Mizuno, Tomoyuki et al. (2013) OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics 14:1141-51
Scott, Jeffrey R; Courter, Joshua D; Saldaña, Shannon N et al. (2013) Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1. Ther Drug Monit 35:332-7
Fukuda, Tsuyoshi; Goebel, Jens; Cox, Shareen et al. (2012) UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit 34:671-9
Diepstraten, Jeroen; Chidambaran, Vidya; Sadhasivam, Senthilkumar et al. (2012) Propofol clearance in morbidly obese children and adolescents: influence of age and body size. Clin Pharmacokinet 51:543-51

Showing the most recent 10 out of 22 publications